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Amyotrophic lateral sclerosis (ALS) is a fatal neurological disorder in humans characterized
by progressive degeneration of skeletal muscle and motor neurons in spinal cord,
brainstem, and cerebral cortex causing skeletal muscle paralysis, respiratory insufficiency,
and death. There are no cures or effective treatments for ALS. ALS can be inherited,
but most cases are not associated with a family history of the disease. Mitochondria
have been implicated in the pathogenesis but definitive proof of causal mechanisms is
lacking. Identification of new clinically translatable disease mechanism-based molecular
targets and small molecule drug candidates are needed for ALS patients. We tested the
hypothesis in an animal model that drug modulation of the mitochondrial permeability
transition pore (mPTP) is therapeutic in ALS. A prospective randomized placebo-controlled
drug trial was done in a transgenic (tg) mouse model of ALS. We explored GNX-4728
as a therapeutic drug. GNX-4728 inhibits mPTP opening as evidenced by increased
mitochondrial calcium retention capacity (CRC) both in vitro and in vivo. Chronic systemic
treatment of G37R-human mutant superoxide dismutase-1 (hSOD1) tg mice with GNX-
4728 resulted in major therapeutic benefits. GNX-4728 slowed disease progression and
significantly improved motor function. The survival of ALS mice was increased significantly
by GNX-4728 treatment as evidence by a nearly 2-fold extension of lifespan (360 days–
750 days). GNX-4728 protected against motor neuron degeneration and mitochondrial
degeneration, attenuated spinal cord inflammation, and preserved neuromuscular junction
(NMJ) innervation in the diaphragm in ALS mice. This work demonstrates that a mPTP-
acting drug has major disease-modifying efficacy in a preclinical mouse model of ALS and
establishes mitochondrial calcium retention, and indirectly the mPTP, as targets for ALS
drug development.
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INTRODUCTION
Mitochondrial mechanisms have been implicated in the
pathogenesis and progression of amyotrophic lateral sclerosis
(ALS; Wong et al., 1995; Bendotti et al., 2001; Beal, 2005; Martin,
2010a; Reddy and Reddy, 2011; Muyderman and Chen, 2014).
Mitochondrial-based mechanisms of disease in ALS might
include failure of intracellular Ca2+ homeostasis, oxidative
stress propagation, energy depletion, perturbed fission-fusion
dynamics, and cell death initiation (Beal, 2005; Reddy and
Reddy, 2011), but it is possible that mitochondrial changes
are indirectly related to disease etiology and are secondary or
bystander events (Morais and De Strooper, 2010; Muyderman
and Chen, 2014). Previous therapeutic studies have approached
the mitochondrial role in ALS using antioxidants, metabolic
boosters, and dietary manipulations, mostly in mouse models
(Reddy and Reddy, 2011), but these approaches generally lacked
specificity for establishing mitochondria or specific components
or properties of mitochondria as disease targets. Recently, drugs
with putative mitochondrial mechanisms of action, such as
dexpramipexole and olesoxime, have failed in human ALS clinical
trials (Cudkowicz et al., 2013; Lenglet et al., 2014), but these drugs
have pleiotropic actions or unclear mitochondrial mechanisms
of action. Well-defined, unequivocal and specific mitochondrial
mechanisms and targets for directed therapeutics and disease
prevention in ALS have remained elusive.
The mitochondrial permeability transition pore (mPTP) is
emerging as a critical player in neurodegenerative disease and
in acute neuropathology (Martin et al., 2009; Martin, 2010a,b).
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While the definitive core components of the mPTP have been
fleeting (Bernardi et al., 2006; Halestrap, 2009), but now thought
to involve the c-subunit ring of the F1F0 ATP synthase (Bonora
et al., 2013; Alavian et al., 2014), a consistent critical regulator
of the mPTP in vivo and in vitro is cyclophilin D (Bernardi
et al., 2006; Halestrap, 2009; Alavian et al., 2014). A cyclophilin
D knockout study was important in establishing mitochondria as
having a direct role in the mechanisms of disease in preclinical
mouse models of ALS (Martin et al., 2009). The mPTP as a target
of therapeutics in ALS (Martin, 2010b) needs to be validated and
then translated to preclinical animal models using meaningful
pharmacologic approaches rather than genetic approaches. Very
few drugs have been validated as compounds specifically targeting
putative components or functions of the mPTP such as CRC. A
class of cinnamic anilide derivatives has been recently synthesized
and identified as mPTP inhibitors endowed with in vivo ther-
apeutic activity in protecting heart mitochondria from calcium
overload and rabbit heart from ischemia (Fancelli et al., 2014).
These compounds are able to inhibit mPTP opening in response
to calcium overload, oxidative stress, and chemical cross-linkers
in isolated mitochondria (Fancelli et al., 2014). We studied GNX-
4728, a cinnamic anilide compound from the same series, which
inhibits the mPTP and protects mitochondria from calcium over-
load by increasing CRC. We then tested GNX-4728 for therapeutic
actions in a transgenic (tg) mouse model of ALS. This study
shows that chronic treatment of G37R-human mutant superoxide
dismutase-1 (hSOD1) tg mice with GNX-4728 strongly protects
against onset of ALS and robustly extends survival with preserva-
tion of motor neuron number, motor neuron mitochondria, and
neuromuscular junction (NMJ) integrity.
MATERIALS AND METHODS
MICE
Adult wildtype non-tg C57BL/6 mice and tg mice were used. Tg
mice were hemizygous for a low copy number of hSOD1-G37R
mutant allele driven by the endogenous human promoter (line
29) derived from a founder B6.Cg-Tg SOD1-G37R 29Dpr/J (stock
# 008229, The Jackson Laboratory, Bar Harbor, MA) as described
(Gertz et al., 2012; Wong et al., 2013). Mice were used with
approval from the institutional Animal Care and Use Committee.
DRUG
GNX-4728 is a substituted cinnamic anilide (Figure 1A) which
belongs to a novel series of potent inhibitors of the mPTP
(Fancelli et al., 2014).
MITOCHONDRIAL CALCIUM RETENTION CAPACITY (CRC) ASSAY
CRC assays were performed on freshly isolated mitochondria
from adult non-tg mouse brain and heart (n = 6) after GNX-4728
was administered intravenously by tail vein injection (15 mg/kg
in 20% DMSO and 40% PEG400) followed by a survival of 5 min.
Control mice (n = 6) were injected with vehicle. Brain and heart
mitochondria were isolated using a similar procedure as described
(Wong et al., 2013). Mitochondrial CRC was assessed fluorimet-
rically in the presence of the fluorescent Ca2+ indicator Calcium
Green 5N (Invitrogen Molecular Probes) using a temperature
controlled Perkin-Elmer LS 55 spectrofluorimeter as described
FIGURE 1 | GNX-4728 general structure and in vivo actions on
mitochondria. (A) General structure of the chemical class of cinnamic
anilide mPTP inhibitors that comprises GNX-4728. (B) Organ (heart and
brain) calcium retention capacity (CRC) assay performed on freshly prepared
mitochondria following systemic treatment of mice with GNX-4728 or
vehicle. CRC was determined by the concentration of calcium required to
trigger mPTP opening. CRC was increased by GNX-4728 in heart (p < 0.05)
and brain (p < 0.01) compared to vehicle (combined organ mitochondria).
(Fancelli et al., 2014). Briefly, purified organ mitochondria were
pulse-loaded with 10 mM calcium and then challenged with
increasing concentrations of calcium until mitochondrial perme-
ability transition was triggered as evidenced by complete release
of mitochondrially-stored calcium due to mPTP opening.
TG MICE AND DRUG TREATMENT PROTOCOL
Cohorts of tg mice expressing mutated G37R-hSOD1 were bred
and identified by genotyping of tail DNA as described (Martin
et al., 2007, 2009; Wong and Martin, 2010). All mice were housed
in the institutional vivarium with generally 4–5 mice per cage
and ad libitum food and water. Starting at 6 months of age,
before the onset of overt symptoms, male G37R-hSOD1 mice
were treated with 300 µg (100 µl) of GNX-4728 or vehicle
(DMSO/cyclodextrin/saline) every other day by intraperitoneal
injection. Only male mice were used because of known gender-
differences in the involvement of the mPTP regulator cyclophilin
D in ALS pathobiology (Martin et al., 2009) and to minimize
burden to the operators treating mice over long-term with indi-
vidual injections. This dosage and treatment regimen was in part
based on preliminary data showing GNX-4728 protection of ALS
mouse spinal cord mitochondria from Ca2+-induced swelling
(Martin et al., unpublished observations). The treatment group
size totals were 18–20 mice, but these mice were divided among
different experiments, including survival studies. The initial ran-
domization was accomplished using the envelope method with
knowledge of litter origin so that individuals from the same
litter could be distributed across groups. Mice were maintained
in the colony and received vehicle or GNX-4728 treatment. For
survival experiments, the vehicle and GNX-4728 group sizes were
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10 and 12, respectively. The mice were observed once a day. The
disease progresses usually from hindleg paraplegia with some
function of the forelimbs remaining. When animals developed
paraplegia, ad libitum nutrigel and chow were placed in the cage,
and water was available at a bottom-cage level drinking spout. At
this time locomotor activity is compromised but the animals can
still ambulate to access food and water. At this stage, the mice
are observed three or more times a day. Endstage disease was
defined as complete lack of locomotor activity, detected within
2–4 h after onset, at which time the mice were euthanized. A
subgroup of mice was killed before endstage to assess the efficacy
of GNX-4728 using histological endpoints. Disease onset was
assessed by running wheel activity and hind-limb paresis. Vehicle
and GNX-4728 treated mice and age-matched non-tg littermate
mice were evaluated for neurologic deficit. They were assessed
at 12 months of age using a voluntary activity wheel (Harvard
Apparatus).
SPINAL CORD AND NEUROMUSCULAR PATHOLOGY
Vehicle and GNX-4728 treated tg mice and naïve mice (n = 5
per group) at 12 months of age were deeply anesthetized and
perfused by cardiac puncture with ice-cold 100 mM phosphate-
buffered normal saline (PBS) followed by 4% paraformaldehyde
in PBS. After perfusion-fixation, mouse bodies were stored at 4◦C
overnight and then the spinal cord and diaphragm were removed
from each mouse. Spinal cords were cryoprotected (20% glycerol)
before they were frozen-sectioned (40 µm) transversely using a
sliding microtome. Serial tissue section arrays were stored indi-
vidually in 96-well plates in anti-freeze buffer. The diaphragm was
removed as a complete tissue sheet (Comerford and Fitzgerald,
1986) and placed in PBS at 4◦C until processed for NMJ
visualization.
Nissl-stained transverse sections of spinal cord were used
to count the number of motor neurons in vehicle and GNX-
4728 treated tg mice and in age-matched littermate non-tg mice.
Spinal cord sections were selected with a random start and
then systematically sampled (every 10th section) to generate a
subsample of sections from each mouse lumbar spinal cord that
was mounted on glass slides and stained with cresyl violet for
cell counting. Nissl-stained motor neurons in ventral horn were
counted by individuals blinded to experimental treatment, using
strict morphological criteria, in digital images acquired with a
Nikon microscope at 200x magnification. These criteria included
a round, open, pale nucleus (not condensed and darkly stained),
globular Nissl staining of the cytoplasm, and a diameter of ∼20–
40 µm. With these criteria, astrocytes, oligodendrocytes, and
microglia were excluded from the counts, but these counts are
likely to estimate the combined populations of α- and γ-motor
neurons.
Mitochondrial pathology was assessed specifically within
spinal cord motor neurons using immunohistochemistry. Free-
floating spinal cord sections from GNX-4728- and vehicle-treated
G37R-hSOD1 tg mice and age-matched non-tg mice were stained
by an immunoperoxidase method with antibodies to the mito-
chondrial matrix marker superoxide dismutase-2 (Stressgen)
and diaminobenzidine as described (Martin et al., 2007). Mito-
chondrial diameters within motor neurons were measured by
individuals blinded to experimental history using ocular filar
micrometry as described (Martin et al., 2007).
Diaphragm motor endplates were visualized with Alexa 594-
conjugated α-bungarotoxin (BTX, Invitrogen, Molecular Probes)
as described (Martin and Liu, 2007). Dual labeling was done
to visualize motor neuron distal axons and their terminals in
whole diaphragm preparations by immunofluorescent detection
of neurofilament protein using a monoclonal antibody (SMI-32,
Convance) and confocal microscopy as described (Martin and
Liu, 2007). The immunofluorescent labeling for neurofilament
was used to determine whether the BTX-labeled motor endplates
were innervated. Confocal microscope images of the typical band
distributions of motor endplates in diaphragm (Comerford and
Fitzgerald, 1986) were scored as innervated (normal) if there
was overlap with the axon terminal or denervated (unoccupied)
if the endplate was not associated with an axon. NMJ imaging
and scoring were performed by individuals unaware of mouse
treatment.
DATA ANALYSIS
The values shown in the graphs represent the mean ± standard
deviation. For histological data, group means and variances were
evaluated statistically by one-way ANOVA and a Student’s t-test.
Time-to-event measures (disease onset and survival duration)
were analyzed using Kaplan-Meier survival fit analysis. The Cox
proportional hazards model was used to analyze the effect of
GNX-4728 on survival and to determine hazard ratios. There was
no censoring of mice due to drug- or treatment-related deaths. A
one-way ANOVA followed by Tukey post-hoc test were used for
statistical comparisons for time-to-event measures.
PHOTOGRAPHY AND FIGURE CONSTRUCTION
The original images used for figure construction were generated
using digital photography. Digital images were captured as TiFF
files using a SPOT digital camera and SPOT Advanced software
(Diagnostic Instruments) or a Nikon digital camera (DXM1200)
and ACT-1 software. Images were altered slightly for brightness
and contrast using ArcSoft PhotoStudio 2000 or Adobe Photo-
shop software without changing the content and actual result.
Figure composition was done using CorelDraw X5 software with
final figures being converted to TiFF files. Files of compos-
ite figures were adjusted for brightness and contrast in Adobe
Photoshop.
RESULTS
GNX-4728 ENHANCES MITOCHONDRIAL CRC
The mPTP blocking activity and blood brain barrier permeability
of GNX-4728 in vivo was assessed by measuring its ability to
prevent isolated calcium pulse-loaded organ mitochondria from
mPTP opening after systemic drug treatment. Mice were treated
with 15 mg/kg GNX-4728 or vehicle iv and, 5 min later, mito-
chondria were isolated from heart and brain and then assayed
for mPTP opening induced by calcium (Figure 1B). Systemic
treatment with GNX-4728 significantly increased mitochondrial
CRC in heart and brain (Figure 1B). The increase in brain
mitochondrial CRC is indicative of the ability of GNX-4728 to
cross the blood-brain barrier (BBB). Other compounds of this
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series were able to protect heart, liver and kidney, but not brain
mitochondria after in vivo administration which supports the
notion that GNX-4728 actively crosses the BBB (data not shown).
GNX-4728 INCREASES LIFESPAN OF ALS MICE
GNX-4728 treatment of G37R-hSOD1 mice strongly protected
against clinical onset of disease and robustly extended survival
compared to littermate vehicle-treated ALS mice (Figure 2). Dis-
ease onset (mean± SD), as assessed by running wheel activity and
hind-limb paresis, was significantly (p< 0.01) delayed with GNX
treatment (381 ± 45 days) vs. vehicle (159 ± 39 days). Median
lifespan (mean ± SD) was significantly (p < 0.01) increased with
GNX treatment (686 ± 120 days) vs. vehicle (366 ± 29 days).
Hazard ratio determinations of the two treatment groups revealed
significantly different hazard rates for the GNX-4728 treated mice
as 0, 0.1, 0.11, 0.12, 0.29, 0.8, and 1.0 at 420, 490, 560, 630, 700,
770, and 840 days of age, respectively (Figure 2). For some ALS
mice treated with GNX-4728 their lifespan was almost doubled
(Figure 2).
GNX-4728 PROTECTS AGAINST SPINAL CORD, MITOCHONDRIAL, AND
DIAPHRAGM PATHOLOGY IN ALS MICE
Twelve-month-old vehicle-treated and GNX-4728-treated ALS
mice and age-matched non-tg mice were evaluated histologi-
cally for motor neuron numbers, mitochondrial swelling, and
inflammatory changes in spinal cord and for NMJ innervations
in diaphragm (Figure 3; Table 1). Nissl-staining was used to
visualize motor neurons in spinal cord (Figures 3A–C). In prepa-
rations of non-tg mice, large spinal motor neurons were promi-
nent and inflammatory changes were not present (Figure 3A).
At 12 months of age, vehicle-treated G37R-SOD1 tg mice were
symptomatic and had about 80% loss of motor neurons in
lumbar spinal cord (Figures 3B,D) and prominent small cell
infiltration and reactive inflammatory changes (Figure 3B). Iba1
immunoreactivity, a marker for inflammation (Zhao et al., 2013),
was significantly elevated in vehicle-treated ALS mouse spinal
cord compared to non-tg control (Figure 3A). In contrast,
FIGURE 2 | Chronic treatment of G37R-human mutant superoxide
dismutase (hSOD1) transgenic mice with GNX-4728 is therapeutic in
ALS. Kaplan-Meier survival plot for age at death in G37R-hSOD1 mice.
GNX-4728 treatment of G37R-hSOD1 mice (n = 12) robustly extended
survival compared to littermate vehicle-treated ALS mice (n = 10). Disease
onsets for vehicle-treated (hatched arrow) and GNX-treated (solid arrow) are
indicated. See text for description of hazards ratios (at graph bottom).
FIGURE 3 | GNX-4728 protects spinal cord motor neurons and
diaphragm neuromuscular junctions (NMJs) in G37R-hSOD1 tg mice.
(A–C) Brightfield microscope images of cresyl violet (Nissl)-stained
lumbar spinal cord sections from a 12-month-old non-tg mouse (A) and
G37R-hSOD1 tg mice that received vehicle (B) or GNX-4728 (C) treatments.
Scale bar (in A) = 40 µm (same for B,C). (D) Graph showing the number of
(Continued )
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FIGURE 3 | Continued
lumbar spinal cord motor neurons in G37R-hSOD1 tg mice that received
vehicle or GNX-4728 (GNX) treatments. Values are mean ± SD
(N = 5/group). Significant differences ∗∗p < 0.001 or ∗p < 0.05 from non-tg
mice. (E–G) Brightfield microscope images of Iba1 (microglial
marker)-immunostained lumbar spinal cord sections from a 12-month-old
non-tg mouse (E) and G37R-hSOD1 tg mice that received vehicle (F) or
GNX-4728 (G) treatments. Scale bar (in E) = 100 µm (same for F,G).
(H) Graph showing the immunodensity of spinal cord Iba1 immunoreactivity
in non-tg mice and G37R-hSOD1 tg mice that received vehicle or GNX-4728
(GNX) treatments. Values are mean ± SD (N = 5/group): significant
difference ∗p < 0.05 from non-tg mice; significant difference +p < 0.05
from vehicle-treated mice. (I–K) Confocal microscope images of diaphragm
NMJs stained for skeletal muscle motor endplates (α-bungarotoxin, red)
and motor neuron axons (neurofilament, green) from a 12-month-old non-tg
mouse (I) and G37R-hSOD1 tg mice that received vehicle (J) or GNX-4728
(K) treatments. Scale bar (in I) = 100 µm (same for J,K). (L) Graph showing
the percent innervation of motor endplates in diaphragm. Significant
difference ∗p < 0.01 from non-tg mice.
Table 1 | GNX-4728 protection of spinal cord motor neuron
mitochondria.
Group Mitochondrial diameter (µm)1
Non-tg 0.4 ± 0.2
G37R-hSOD1 Vehicle 1.6 ± 0.6∗∗
G37R-hSOD1 GNX-4728 0.7 ± 0.4∗
1Values are mean ± standard deviation. ∗GNX4728 vs. non-tg and vehicle,
p < 0.05. ∗∗Vehicle vs. non-tg, p < 0.01.
12-month-old GNX-4728-treated ALS mice had significant
preservation of motor neurons (Figures 3C,D) and significantly
attenuated inflammation as evidenced by the diminished Iba1
immunoreactivity (Figures 3F–H).
To assess the ability of GNX-4728 to protect mitochondria
directly within motor neurons we used immunohistochemistry
to detect the mitochondrial marker SOD2 and measured mito-
chondrial diameters. In non-tg mouse spinal motor mitochondria
are about 0.4–0.5 µm in diameter (Table 1), consistent with
previous observations (Martin et al., 2007). In 12-month-old
vehicle-treated G37R-hSOD1 tg mice, mitochondrial diameters
were increased significantly compared to age-matched non-tg
mice (Table 1). GNX-4728 significantly protected against mito-
chondrial swelling in G37R-hSOD1 tg mouse spinal motor neu-
rons (Table 1).
To assay for whether GNX-4728 protects NMJs in ALS mice,
a whole-mount diaphragm preparation was used. In non-tg
mice, motor endplate innervation of diaphragm was near 100%
(Figures 3I,L), while in vehicle-treated ALS mice endplate inner-
vation was only about 20% (Figures 3J,L). In contrast, in GNX-
4728-treated ALS mice, NMJ innervation was restored to about
80% of non-tg control (Figures 3K,L).
DISCUSSION
Our study demonstrates that a small molecule cinnamic anilide
derivative, GNX-4728, has several major therapeutic benefits in a
mouse model of ALS. GNX-4728 increased brain mitochondrial
CRC in vivo after systemic administration. Importantly from a
preclinical perspective, chronic systemic treatment of ALS mice
with GNX-4728 resulted in the following: (1) a delay in disease
onset; (2) dramatically increased lifespan; (3) protection of spinal
cord motor neurons; (4) protection of spinal cord motor neuron
mitochondria; (5) block of spinal cord inflammatory changes;
and (6) preservation of NMJs in diaphragm. These results are
particularly exciting because they support the concept of the
mPTP as a practical drugable therapeutic target in ALS in vivo
and demonstrate that cinnamic anilides could be a future avenue
to the effective treatment of ALS.
In this study we used a tg mouse model of ALS to test the
therapeutic efficacy of GNX-4728. These mice express a low
copy number of hSOD1-G37R mutant allele in a non-conditional
expression pattern throughout the body (Wong et al., 1995).
This mouse model is very different from the hSOD1-G93A tg
mouse model that expresses the mutant allele at a very high
copy number and consequently have an aggressive disease and a
lifespan of only about 4 months (Gurney et al., 1994). Because
of the rapidity of the disease course, the hSOD1-G93A high-
expresser tg mouse has been the most commonly used mouse
model to assess ALS therapeutics. However, although these mice
develop a fatal paralysis and show a very prominent lower motor
neuron disease (Gurney et al., 1994; Bendotti et al., 2001; Martin
et al., 2007), the details of the cellular and molecular pathology
appear to be distinct from that seen in human ALS (Martin,
1999, 2010a; Martin and Liu, 2004; Martin et al., 2007). These
differences might contribute to the lack of success in the clinical
translation of drugs shown to have therapeutic efficacy in the
hSOD1-G93A tg mouse model. Therefore, we used, instead of the
high-expressing hSOD1-G93A tg mouse line, the hSOD1-G37R
mouse line with a much longer lifespan. The major downsides
of using the longer-lived mouse line is the time commitment for
drug treatments and the modeling of only a subtype of familial
ALS caused by a mutated hSOD1 gene.
We found that GNX-4728 improved neurologic function and
survival of ALS mice. The effect on lifespan was robust. A limita-
tion of the current study is the relative small group sizes for the
survival analysis, as it would have been better to have doubled the
number of animals in each group. Few pharmacological studies
have been done using the hSOD1-G37R mouse line, and the most
notable study showed that mice fed chow containing a cocktail of
riluzole, nimodipine, and minocycline had about a 15% increase
in maximal lifespan (Kriz et al., 2003). This modest effect might
be due to the lack of direct disease mechanism-based targeting.
In fact, treatment of human ALS patients with riluzole, a sodium
channel antagonist with anti-glutamatergic actions, prolongs life
by only about 2–3 months in some patients, but there is no visible
functional improvement (Bensimon et al., 1994). Questions per-
sist about the clinical usefulness of riluzole because of its modest
effects and high cost (Miller et al., 2012). Another anti-glutamate
drug, gabapentin, failed in clinical trials (Miller et al., 2001). Thus,
a role for glutamate and excitotoxicity in the direct mechanisms
of ALS is appearing tenuous (Martin, 2010a), and the concept
has so far failed to bear effective therapeutic fruit after more
than 20 years (Rothstein et al., 1992). Other disease-mechanism
concepts need to be considered to potentially move the treatment
of ALS forward. A role for the mPTP in the mechanism of ALS
is an attractive concept that can bring together old and new
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ideas regarding cell degeneration in ALS including, intracellular
calcium dysregulation, mitochondria, oxidative stress, and pos-
sibly excitotoxicity (Martin, 2010a,b; Reddy and Reddy, 2011).
In the current preclinical animal model study, we attribute the
success of GNX-4728 to its actions on mitochondria. It penetrated
the BBB and increased mitochondrial CRC in brain, revealed by
the increased threshold for calcium-induced permeability tran-
sition, suggesting that GNX-4728 is operating by inhibiting the
mPTP. Striated muscle mitochondrial CRC was also increased.
Genetic studies have revealed the participation of the mPTP in
the mechanisms of disease in mouse models of ALS (Martin et al.,
2009). Other studies support the role of mitochondrial calcium
dysregulation and mPTP activation in the mechanisms of ALS
(Bendotti et al., 2001; Jaiswal and Keller, 2009; Barrientos et al.,
2011; Nguyen et al., 2011; Bartolome et al., 2013; Muyderman and
Chen, 2014). The finding that GNX-4728 bocks mitochondrial
swelling directly within motor neurons and protects these cells
further points to the mPTP as a target of disease in ALS and
that GNX-4728 is possibly providing therapeutic benefit through
modulation of mPTP function.
GNX-4728 was delivered systemically in our study. Its ther-
apeutic activity could be within the CNS, because of its BBB
permeability, at peripheral locations (skeletal muscle and nerves),
or both. It could be acting at skeletal muscle mitochondria to
provide therapeutic effects. Skeletal muscle is also a primary
site of disease in mouse models of ALS (Dobrowolny et al.,
2008; Wong and Martin, 2010; Luo et al., 2013) and possibly in
human ALS (Vielhaber et al., 2000). Mitochondria within skeletal
muscle of ALS mice show early abnormalities in calcium signaling
capacity (Zhou et al., 2010), DNA methylation and autophagy
(Wong et al., 2013), and metabolism (Dupuis et al., 2006). Addi-
tional studies need to address the potential effects of GNX-4728
and non-BBB permeable cinnamic anilides in skeletal muscle of
ALS mice.
Despite evidence derived from human ALS and mouse and
cells models of ALS indicating that mitochondria have a role
in disease pathogenesis (Beal, 2005; Martin, 2010a; Reddy and
Reddy, 2011), recent human ALS clinical trials with putative mito-
chondrial acting drugs have been unsuccessful. Dexpramipex-
ole and olesoxime both failed to show significant benefits in
ALS patients (Cudkowicz et al., 2013; Lenglet et al., 2014).
Dexpramipexole can act on brain mitochondria to increase the
efficiency of oxidative phosphorylation (Alavian et al., 2012).
Olesoxime has pleiotropic actions. It protects neurons from
trophic factor and target deprivation and apoptosis (Bordet et al.,
2007; Martin et al., 2011). Olesoxime binds proteins in the
outer mitochondrial membrane (Bordet et al., 2007, 2010), but
it does not increase mitochondrial CRC (Bordet et al., 2010).
Thus, the failure of dexpramipexole and olesoxime as therapies
for human ALS could be due to their inability to modulate
mitochondrial CRC.
To our knowledge, no other experimental drug or experimen-
tal manipulation has shown this level of therapeutic efficacy in
ALS mice. We have not observed untoward side-effects in vivo,
even after chronic treatment of mice. This study identifies a new
drug class, cinnamic anilides, which might be promising for the
treatment of ALS. Future experiments are warranted that test the
efficacy of GNX-4728-like compounds in other mouse models of
ALS to assess their potential general application for the treatment
of different forms of ALS.
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